Abbott Vascular Press Kit
This page has been provided for media purposes only and in conjunction with press related activities.
Press Releases
- Abbott's XIENCE V™ Drug Eluting Stent Outperforms TAXUS® in Key Efficacy and Safety Endpoints Out to Two Years
- New
Data Shows Abbott's Bioabsorbable Drug Eluting Stent Is Absorbed Within Two
Years – Leaving Behind Functioning Blood Vessels
- Abbott Begins Post-Approval Study of XIENCE V Drug Eluting Stent
- FDA Approves Abbott's XIENCETM V Drug Eluting Stent
- Abbott Submits Application for Approval of XIENCETM V Everolimus Eluting Coronary Stent System in Japan
- Abbott Launches Next-Generation StarClose® SE Vascular Closure System
- XIENCETM V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
- XIENCETM V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
- FDA Approves Abbott's XIENCE™ V Drug Eluting Stent
- Study in JAMA Shows Patients Treated with Abbott's XIENCE™ V Drug Eluting Stent Experience Better Outcomes than Patients Treated with Market-Leading Drug Eluting Stent
- Abbott's XIENCE™ V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
- The Lancet Publishes Results from World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Abbott Receives CE Mark for Smaller-Size XIENCE™ V Drug Eluting Stent
- Abbott Gains Reimbursement for XIENCE™ V Drug Eluting Stent in France
- Abbott to Initiate First Study to Evaluate XIENCE™ V Everolimus Eluting Coronary Stent System in Treatment of Women with Cardiovascular Disease
- Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Abbott Announces Positive Six-Month Results from the World's First Clinical Trial of A Fully Bioabsorbable Drug-Eluting Coronary Stent
Fact Sheets
- ABSORB Fact Sheet
- SPIRIT Trial Fact Sheet
- Vascular Terms Fact Sheet
- Vision Fact Sheet
- Xience V Fact Sheet
- Quick Facts on Stroke
- Quick Facts on Carotid Artery Disease
- Quick Facts on Carotid Artery Disease Treatment Options
- Carotid Trials Fact Sheet
- Carotid Program Fact Sheet
- Coronary Artery Disease (CAD) Fact Sheet
- Coronary Artery Stenting Fact Sheet
- Glossary of Vascular Terms
Illustrations
Abbott's Bioabsorbable Everolimus Eluting Stent Images
) Abbott's Bioabsorbable Everolimus Eluting Stent Enlarge Image |
) ABSORB Animation Still 1 Enlarge Image |
) ABSORB Animation Still 2 Enlarge Image |
) Abbott's Bioabsorbable Everolimus Eluting Stent Enlarge Image |
XIENCE V Everolimus Eluting Coronary Stent System Images
) XIENCE V Illustration Enlarge Image |
) XIENCE V Crimped Enlarge Image |
) XIENCE V Expanded Enlarge Image |
) XIENCE V in Vessel Enlarge Image |
) XIENCE V on Balloon Enlarge Image |
) XIENCE V Box Enlarge Image |
) XIENCE V Production Enlarge Image |
) XIENCE V Enlarge Image |
Carotid Product Images
) Emboshield Embolic Protection System Enlarge Image |
) Xact Carotid Stent Enlarge Image |
) RX Accunet Embolic Protection System Enlarge Image |
)
RX Acculink Carotid Stents Enlarge Image |
B-Roll
For FTP access to B-roll footage of Abbott's bioabsorbable and XIENCE V stent systems,
please contact Karin Bauer at (408) 845-3887.
Media Contact Information
Media Contact Information
Jonathon Hamilton (408) 845-3491
Karin Bauer (408) 845-3887
Jennie Kim (408) 845-1755
Investor Contact Information
John Thomas, (847) 938-2655
Tina Ventura, (847) 935-9390
AP2928717 Rev. B
){kind=link}